Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.76 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | NAMPT | P43490 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | GSK3A | P49840 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22601457 | 0.86 | LMNA (1.00) | LMNANPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL22601573 | 0.83 | LMNA (0.79) | LMNANPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL16881794 | 0.83 | NPC1 (0.75) | LMNANPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL18125241 | 0.81 | NPC1 (0.67) | LMNANPC1RAB9ASMN1; SMN2NAMPT | |
| SCHEMBL22601558 | 0.81 | LMNA (0.74) | LMNANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL16703342 | 0.80 | CYP11B1 (0.65) | LMNANPC1RAB9ANAMPTALDH1A1 | |
| SCHEMBL22601460 | 0.80 | LMNA (0.82) | LMNANPC1RAB9ASMN1; SMN2NAMPT | |
| SCHEMBL18125250 | 0.79 | GSK3B (0.65) | LMNANPC1RAB9ASMN1; SMN2NAMPT | |
| SCHEMBL22601544 | 0.79 | LMNA (0.85) | LMNANPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL22601584 | 0.78 | LMNA (0.80) | LMNANPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | HEPAGENE THERAPEUTICS, INC. (VG) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | ATF1, ERN1, MAP3K1 | LMNA 3233/4885NPC1 1692/4885RAB9A 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.